Antenatal Noninvasive DNA Testing: Clinical Experience and Impact

Millie A. Ferres; Lisa Hui; Diana W. Bianchi

doi:10.1055/s-0034-1371706

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2014; 31(07): 577-582
DOI: 10.1055/s-0034-1371706

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Antenatal Noninvasive DNA Testing: Clinical Experience and Impact

Authors

Millie A. Ferres

¹Mother Infant Research Institute, Tufts Medical Center and Floating Hospital for Children, Tufts University School of Medicine, Boston, Massachusetts

²Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts

³Department of Obstetrics and Gynecology, Tufts University School of Medicine, Boston, Massachusetts
Lisa Hui

⁴Mercy Hospital for Women, Heidelberg, Victoria, Australia

⁵Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia
Diana W. Bianchi

¹Mother Infant Research Institute, Tufts Medical Center and Floating Hospital for Children, Tufts University School of Medicine, Boston, Massachusetts

²Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts

³Department of Obstetrics and Gynecology, Tufts University School of Medicine, Boston, Massachusetts

Abstract

Background Nearly two decades ago, the discovery of circulating cell-free fetal DNA in maternal blood created a paradigm shift in prenatal testing. Recent advances in DNA sequencing technology have facilitated the rapid translation of DNA-based testing into clinical antenatal care.

Content In this review, we summarize the technical approaches and current clinical applications of noninvasive testing using cell-free DNA in maternal plasma. We discuss the impact of these tests on clinical care, outline proposed integration models, and suggest future directions for the field.

Summary The use of cell-free DNA in maternal blood for the detection of fetal rhesus D antigen status, fetal sex, and common whole chromosomal aneuploidies is now well established, although testing for aneuploidy is still considered screening and not diagnostic. Further advances in technology and bioinformatics may see future clinical applications extend to the noninvasive detection of fetal subchromosomal aneuploidy, single gene disorders, and the entire fetal genome.

Keywords

cell-free fetal DNA - prenatal screening - noninvasive prenatal testing - NIPD - NIDT - pregnancy

Volltext

Referenzen

References
1 Lo YM, Corbetta N, Chamberlain PF , et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350 (9076) 485-487
2 Fan HC, Quake SR. Detection of aneuploidy with digital polymerase chain reaction. Anal Chem 2007; 79 (19) 7576-7579
3 Lo YM, Lun FM, Chan KC , et al. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci U S A 2007; 104 (32) 13116-13121
4 Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A 2008; 105 (42) 16266-16271
5 Chiu RW, Chan KC, Gao Y , et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 2008; 105 (51) 20458-20463
6 Chiu RW, Akolekar R, Zheng YW , et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011; 342: c7401
7 Ehrich M, Deciu C, Zwiefelhofer T , et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204 (3) e1-e11
8 Sehnert AJ, Rhees B, Comstock D , et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011; 57 (7) 1042-1049
9 Palomaki GE, Kloza EM, Lambert-Messerlian GM , et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13 (11) 913-920
10 Sparks AB, Wang ET, Struble CA , et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012; 32 (1) 3-9
11 Palomaki GE, Deciu C, Kloza EM , et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012; 14 (3) 296-305
12 Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP ; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119 (5) 890-901
13 Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206 (4) e1-e5
14 Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206 (4) e1-e9
15 Norton ME, Brar H, Weiss J , et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207 (2) e1-e8
16 Dan S, Wang W, Ren J , et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 2012; 32 (13) 1225-1232
17 Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med 2012; 18 (7) 1041-1051
18 Scheffer PG, van der Schoot CE, Page-Christiaens GC, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011; 118 (11) 1340-1348
19 Clausen FB, Christiansen M, Steffensen R , et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012; 52 (4) 752-758
20 Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012; 120 (2 Pt 1) 227-234
21 Rijnders RJ, van der Schoot CE, Bossers B, de Vroede MA, Christiaens GC. Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstet Gynecol 2001; 98 (3) 374-378
22 Santacroce R, Vecchione G, Tomaiyolo M , et al. Identification of fetal gender in maternal blood is a helpful tool in the prenatal diagnosis of haemophilia. Haemophilia 2006; 12 (4) 417-422
23 Hill M, Lewis C, Jenkins L, Allen S, Elles RG, Chitty LS. Implementing noninvasive prenatal fetal sex determination using cell-free fetal DNA in the United Kingdom. Expert Opin Biol Ther 2012; 12 (Suppl. 01) S119-S126
24 Lo YM, Chan KC, Sun H , et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010; 2 (61) 61ra91
25 Srinivasan A, Bianchi DW, Huang H, Sehnert AJ, Rava RP. Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. Am J Hum Genet 2013; 92 (2) 167-176
26 Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X and Y using targeted sequencing of polymorphic loci. Prenat Diagn 2013; 33: 575-579
27 Nicolaides KH, Syngelaki A, Gil MM, Quezada MS, Zinevich Y. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Fetal Diagn Ther 2013; (e-pub ahead of print). doi: 10.1159/000355655
28 Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn 2013; 33 (6) 569-574
29 Malone FD, Canick JA, Ball RH , et al; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353 (19) 2001-2011
30 Benn P, Borell A, Chiu RW , et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013; 33 (7) 622-629
31 The American College of Obstetricians and Gynecologists Committee of Genetics; The Society for Maternal Fetal Medicine Publications Committee. Committee Opinion. No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol. 2012; Dec; 120 (6) 1532-1534 . doi: 10.1097/01.AOG.0000423819.85283.f4
32 Fairbrother G, Johnson S, Musci TJ, Song K. Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn 2013; 33 (6) 580-583
33 Song Y, Liu C, Qi H, Zhang Y, Bian X, Liu J. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn 2013; 33 (7) 700-706
34 Walsh JM, Goldberg JD. Fetal aneuploidy detection by maternal plasma DNA sequencing: a technology assessment. Prenat Diagn 2013; 33 (6) 514-520
35 Srinivasan A, Bianchi DW, Liao W, Sehnert AJ, Rava RP. Maternal plasma DNA sequencing: effects of multiple gestation on aneuploidy detection and the relative cell-free fetal DNA (cffDNA) per fetus. Am J Obstet Gynecol 2013; 208: S31
36 Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012; 207 (5) e1-e6
37 Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013; 42 (1) 41-50
38 Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013; 33 (6) 542-546
39 Bianchi D, Wilkins-Haug L. Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road?. Clin Chem 2014; 60 (1) 78-87
40 Hahnemann JM, Vejerslev LO. Accuracy of cytogenetic findings on chorionic villus sampling (CVS)—diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to EUCROMIC 1986-1992. Prenat Diagn 1997; 17 (9) 801-820
41 Faas BH, de Ligt J, Janssen I , et al. Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. Expert Opin Biol Ther 2012; 12 (Suppl. 01) S19-S26
42 Osborne CM, Hardisty E, Devers P , et al. Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat Diagn 2013; 33 (6) 609-611
43 Bianchi DW, Prosen T, Platt LD , et al; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma. Obstet Gynecol 2013; 121 (5) 1057-1062
44 Mazloom AR, Džakula Z, Oeth P , et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn 2013; 33 (6) 591-597
45 Samango-Sprouse C, Banjevic M, Ryan A , et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn 2013; 33 (7) 643-649
46 Guex N, Iseli C, Syngelaki A , et al. A robust second-generation genome-wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in maternal blood. Prenat Diagn 2013; 33 (7) 707-710
47 Yu SC, Jiang P, Choy KW , et al. Noninvasive prenatal molecular karyotyping from maternal plasma. PLoS ONE 2013; 8 (4) e60968
48 Jensen TJ, Dzakula Z, Deciu C, van den Boom D, Ehrich M. Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma. Clin Chem 2012; 58 (7) 1148-1151
49 Lench N, Barrett A, Fielding S , et al. The clinical implementation of non-invasive prenatal diagnosis for single-gene disorders: challenges and progress made. Prenat Diagn 2013; 33 (6) 555-562
50 Snyder MW, Simmons LE, Kitzman JO , et al. Noninvasive fetal genome sequencing: a primer. Prenat Diagn 2013; 33 (6) 547-554